Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Perceptual Decisions in the Presence of Relevant and Irrelevant Sensory Evidence.

Anders UM, McLean CS, Ouyang B, Ditterich J.

Front Neurosci. 2017 Nov 10;11:618. doi: 10.3389/fnins.2017.00618. eCollection 2017.

2.

Gene and MicroRNA Expression Responses to Exercise; Relationship with Insulin Sensitivity.

McLean CS, Mielke C, Cordova JM, Langlais PR, Bowen B, Miranda D, Coletta DK, Mandarino LJ.

PLoS One. 2015 May 18;10(5):e0127089. doi: 10.1371/journal.pone.0127089. eCollection 2015.

3.

Anti-tumour therapeutic efficacy of OX40L in murine tumour model.

Ali SA, Ahmad M, Lynam J, McLean CS, Entwisle C, Loudon P, Choolun E, McArdle SE, Li G, Mian S, Rees RC.

Vaccine. 2004 Sep 9;22(27-28):3585-94.

PMID:
15315837
4.

Preclinical evaluation of DISC-GMCSF for the treatment of breast carcinoma.

Loudon PT, McLean CS, Martin G, Curry J, Leigh Shaw M, Hoogstraten C, Verdegaal E, Osanto S.

J Gene Med. 2003 May;5(5):407-16.

PMID:
12731089
6.

Preclinical safety testing of DISC-hGMCSF to support phase I clinical trials in cancer patients.

Loudon PT, Blakeley DM, Boursnell ME, Day DA, Duncan IA, Lowden RC, McLean CS, Martin G, Miller JC, Shaw ML.

J Gene Med. 2001 Sep-Oct;3(5):458-67.

PMID:
11601759
7.

Preclinical evaluation of "whole" cell vaccines for prophylaxis and therapy using a disabled infectious single cycle-herpes simplex virus vector to transduce cytokine genes.

Ali SA, McLean CS, Boursnell ME, Martin G, Holmes CL, Reeder S, Entwisle C, Blakeley DM, Shields JG, Todryk S, Vile R, Robins RA, Rees RC.

Cancer Res. 2000 Mar 15;60(6):1663-70.

8.

Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancer.

Boursnell ME, Entwisle C, Ali SA, Sivasubramaniam SD, Reeder S, McLean CS, Blakeley DM, Miller J, Hill S, Shields JG, Inglis SC, Rees RC.

Adv Exp Med Biol. 1998;451:379-84. No abstract available.

PMID:
10026900
9.

A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease.

Boursnell ME, Entwisle C, Blakeley D, Roberts C, Duncan IA, Chisholm SE, Martin GM, Jennings R, Ni Challanaín D, Sobek I, Inglis SC, McLean CS.

J Infect Dis. 1997 Jan;175(1):16-25.

PMID:
8985191
10.

Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer.

Boursnell ME, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC.

Vaccine. 1996 Nov;14(16):1485-94.

PMID:
9014288
11.

Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine.

McLean CS, Ni Challan√°in D, Duncan I, Boursnell ME, Jennings R, Inglis SC.

Vaccine. 1996 Jul;14(10):987-92.

PMID:
8873393
12.

Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.

McLean CS, Erturk M, Jennings R, Challanain DN, Minson AC, Duncan I, Boursnell ME, Inglis SC.

J Infect Dis. 1994 Nov;170(5):1100-9.

PMID:
7963701
13.

Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.

Farrell HE, McLean CS, Harley C, Efstathiou S, Inglis S, Minson AC.

J Virol. 1994 Feb;68(2):927-32.

14.

Delayed-type hypersensitivity response to the human papillomavirus type 16 E7 protein in a mouse model.

McLean CS, Sterling JS, Mowat J, Nash AA, Stanley MA.

J Gen Virol. 1993 Feb;74 ( Pt 2):239-45.

PMID:
8381463
15.

A critical review of comprehensive health screening in adolescents.

Cromer BA, McLean CS, Heald FP.

J Adolesc Health. 1992 Mar;13(2 Suppl):1S-65S. Review. No abstract available.

PMID:
1606168
16.

Identification of the nuclear localization signal of human papillomavirus type 16 L1 protein.

Zhou J, Doorbar J, Sun XY, Crawford LV, McLean CS, Frazer IH.

Virology. 1991 Dec;185(2):625-32.

PMID:
1660197
17.

Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus.

McLean CS, Churcher MJ, Meinke J, Smith GL, Higgins G, Stanley M, Minson AC.

J Clin Pathol. 1990 Jun;43(6):488-92.

18.

Evaluating the sexually active adolescent: identification of behavioral and biologic risk factors.

McLean CS, Farmer M.

Md Med J. 1988 Dec;37(12):933-7. No abstract available.

PMID:
3231015
19.
20.

The use of monoclonal antibodies in (reverse) passive haemagglutination tests for herpes simplex virus antigens and antibodies.

Cranage MP, McLean CS, Buckmaster EA, Minson AC, Wildy P, Coombs RR.

J Med Virol. 1983;11(4):295-306.

PMID:
6308140
21.

Group treatment for parents of the adult mentally ill.

McLean CS, Greer K, Scott J, Beck JC.

Hosp Community Psychiatry. 1982 Jul;33(7):564-8.

PMID:
7106719
22.

Pathogenesis of herpes simplex virus in congenitally athymic mice: the relative roles of cell-mediated and humoral immunity.

Kapoor AK, Nash AA, Wildy P, Phelan J, McLean CS, Field HJ.

J Gen Virol. 1982 Jun;60(Pt 2):225-33.

PMID:
6286849

Supplemental Content

Loading ...
Support Center